Serena Astore

A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: A review of current and investigational treatment for HR+/Her2- breast cancer

Serena Astore, Ester Oneda, Alberto Zaniboni

it (code pays fourni par la source)

Which therapy in biliary tract cancer? Review of main concerns in diagnosis and choice of therapy in advanced setting, current standard, and new options

Ester Oneda, Serena Astore, Laura Gandolfi, Laura Melocchi et autres

The incidence of biliary tract cancer is increasing in developed countries and is generating renewed interest in the scientific community due to the evidence of a high percentage (approximately 40%) of potentially targetable molecular alterations. However, to date, patient selection and the …

it (code pays fourni par la source)

MP60-19 ONCOLOGICAL OUTCOMES OF LOW VOLUME CRPC: RESULTS FROM A LONGITUDINAL REAL-LIFE MULTICENTER COHORT

Maria Consiglia Ferriero, Giuseppe Chiacchio, Riccardo Mastroianni, Leonardo Misuraca et autres

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60)1 May 2024MP60-19 ONCOLOGICAL OUTCOMES OF LOW VOLUME CRPC: RESULTS FROM A LONGITUDINAL REAL-LIFE MULTICENTER COHORT Maria Consiglia Ferriero, Giuseppe Chiacchio, Riccardo Mastroianni, Leonardo Misuraca, Alfredo Maria Bove, Umberto Anceschi, Aldo …

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors

Brigida Anna Maiorano, Massimo Di Maïo, Linda Cerbone, Evaristo Maiello et autres

Importance: Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD-L1) with response and survival in patients treated with ICIs is still controversial. Objectives: To evaluate the association of PD-L1 with …

it (code pays fourni par la source)

Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort

Mariaconsiglia C. Ferriero, Francesco Prata, Umberto Anceschi, Serena Astore et autres

Registrative trials recommended the use of upfront chemotherapy in high-volume metastatic prostate cancer. We reported survival outcomes of patients with high-volume mCRPC treated with ARTA in a chemo-naïve setting compared to patients treated with chemotherapy as first-line from a longitudinal real-life multicenter …

it (code pays fourni par la source)

Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Serena Astore, Giulia Baciarello, Linda Cerbone, Fabio Calabrò

The introduction of first-line combinations had improved the outcomes for metastatic renal cell carcinoma (mRCC) compared to sunitinib. However, some patients either have inherent resistance or develop resistance as a result of the treatment. Depending on the kind of therapy employed, many …

lb, it, my (code pays fourni par la source)

The incidence of vestibular neuritis in Italy

Marco Mandalà, Lorenzo Salerni, Fabio Ferretti, Ilaria Bindi et autres

Objective This study aims to estimate the incidence of Vestibular neuritis (VN) in three different districts in Italy, its epidemiological features, and the prevalence of comorbidities associated with it. Methods An observational prospective study of 198 patients referred to ENT departments in …

it (code pays fourni par la source)

Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study.

Chiara Ciccarese, Sebastiano Buti, Michela Roberto, Fabio Calabrò et autres

714 Background: Intermediate IMDC group is the largest and most heterogeneous group of mRCC. Current first-line (1L) therapy options for these patients (pts) are based on either an anti-angiogenic agent (VEGFR-TKI) combined with immunotherapy (IO), or a combo of IO (ipilimumab+nivolumab [I/N]). …

it (code pays fourni par la source)

Lack of interaction of the fluorosurfactant C6O4 with human renal transporters: In vitro/in silico analysis

Stefania Bruno, Matteo Bersani, Serena Astore, Giulia Chiabotto et autres

C6O4 is a water soluble perfluoroether carboxylic acid ammonium salt used as surfactant in the synthesis of fluoropolymers. Available experimental data in rats exposed by the oral route indicate it is eliminated in urine. Previous studies with various linear perfluorocarboxylic acids have …

it (code pays fourni par la source)

Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations

Roberto Iacovelli, Chiara Ciccarese, Giuseppe Procopio, Serena Astore et autres

it (code pays fourni par la source)

Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?

Chiara Ciccarese, Roberto Iacovelli, Sebastiano Buti, Francesca Primi et autres

BACKGROUND/AIM: Recent evidence suggests potential synergistic antitumor effects of the combination of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors with the oral hypoglycemic agent metformin. The aim of this study was to investigate the safety and activity of metformin combined …

it (code pays fourni par la source)

Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis

Chiara Ciccarese, Roberto Iacovelli, Camillo Porta, Giuseppe Procopio et autres

it (code pays fourni par la source)